ALFA Finder| Execution period | 12 months |
|---|
NSE filing, NSE: MEDICAMEQ. Summary written from the filing by ALFA Finder's alert engine.
Medicamen Biotech Ltd: key numbers
- Share price
- ₹275.45
- Market cap
- ₹387.4 Cr
- Revenue (annual)
- ₹197.8 Cr
- Net profit (annual)
- ₹9.64 Cr
- P/E (TTM)
- 35.8×Sector 43.8×
- Promoter holding
- 42.57%+2.11% QoQ
- FII holding
- 4.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medicamen Biotech Ltd
All →Medicamen Biotech Board Meeting Date
Medicamen Biotech will meet on 13 Nov 2026 to consider half-yearly results for September 2026. Trading window stays closed from 01 Oct to 16 Nov 2026.
Medicamen Biotech Preferential Issue
Medicamen Biotech allotted 50 lakh equity shares at ₹530 per share under its preferential issue. The allotment raises ₹265 Crore in fresh equity capital.
- Value
- ₹265.0 Cr
Medicamen Biotech Preferential Issue
Medicamen Biotech allotted 5,00,000 equity shares at ₹530 each in a preferential issue to one investor. The allotment raised ₹26.5 Crore, taking paid-up capital to ₹14.06 Crore.
- Value
- ₹26.50 Cr
Medicamen Biotech Convertible Warrants
Medicamen Biotech allotted 5,00,000 equity shares to Shivalik Rasayan Ltd via warrant conversion at ₹530 each, raising ₹26.5 Crore. Paid-up capital rises to ₹14.06 Crore.
- Value
- ₹26.50 Cr
Medicamen Biotech Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended 30 September 2026.
Medicamen Biotech Other Announcement
Medicamen Biotech Limited's Director Sanjay Bansal sold 32,813 shares on the open market, as per a regulatory filing.
- Value
- ₹1.05 Cr
Other board meeting outcome announcements
All →Balmer Lawrie Investments Board Meeting Outcome
Balmer Lawrie Investments appointed M/s. K. K. Chanani & Associates as Statutory Auditor for FY 2026-27 under Section 139(5), per a C&AG letter. The appointment is effective from 10 November 2026.
- Execution
- FY 2026-27
Jiwanram Sheoduttrai Industries Board Meeting Outcome
Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.
Finolex Cables Board Meeting Outcome
Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).
Chatterbox Technologies Board Meeting Outcome
Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.
BCC Fuba India Board Meeting Outcome
BCC Fuba India's board met on November 6, 2026 and took note of consolidated related party transactions for the half year ended September 30, 2026. No financial results, capital raise or other material decision was reported.
Voltas Board Meeting Outcome
Voltas Limited's board approved Deloitte Haskins & Sells as statutory auditors for five years from the 73rd AGM, replacing SRBC & Co. LLP, whose second and final term ends at that AGM. Subject to shareholder approval.
- Execution
- Five years: financial years 2027-28 to 2031-32 (from the 73rd AGM in 2027 to the 78th AGM in 2032)